CMPDA - CAS 380607-77-2
Catalog number: 380607-77-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
CMPDA is a positive allosteric modulator of AMPA receptors. Binds at the modulator binding pocket located at the interdimer interface and the clamshell hinges.
Canonical SMILES:
1.A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z;Yang Z;Passaniti A;Lapidus RG;Liu X;Cullen KJ;Dan HC Oncotarget. 2016 May 31;7(22):31892-906. doi: 10.18632/oncotarget.7441.
The overexpression or mutation of epidermal growth factor receptor (EGFR) has been associated with a number of cancers, including head and neck squamous cell carcinoma (HNSCC). Increasing evidence indicates that both the phosphatidylinositol-3-kinase (PI3K)-Akt-mammalian target of Rapamycin (mTOR) and the nuclear factor-kappa B (NF-κB) are constitutively active and contribute to aggressive HNSCC downstream of EGFR. However, whether these two oncogenic signaling pathways exhibit molecular and functional crosstalk in HNSCC is unclear. Our results now reveal that mTORC1, not mTORC2, contributes to NF-κB activation downstream of EGFR/PI3K/Akt signaling. Mechanistically, mTORC1 enhances the inhibitor of nuclear factor kappa-B kinase (IKK) activity to accelerate NF-κB signaling. Concomitantly, activated NF-κB/IKK up-regulates EGFR expression through positive feedback regulation. Blockage of NF-κB/IKK activity by the novel IKKβ specific inhibitor, CmpdA, leads to significant inhibition of cell proliferation and induction of apoptosis. CmpdA also sensitizes intrinsic cisplatin-resistant HNSCC cells to cisplatin treatment. Our findings reveal a new mechanism by which EGFR/PI3K/Akt/mTOR signaling promotes head and neck cancer progression and underscores the need for developing a therapeutic strategy for targeting IKK/NF-κB either as a single agent or in combination with cisplatin in head and neck cancer.
2.IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity.
Bassères DS;Ebbs A;Cogswell PC;Baldwin AS Genes Cancer. 2014 Apr;5(1-2):41-55.
Activating mutations in KRAS are prevalent in cancer, but therapies targeted to oncogenic RAS have been ineffective to date. These results argue that targeting downstream effectors of RAS will be an alternative route for blocking RAS-driven oncogenic pathways. We and others have shown that oncogenic RAS activates the NF-κB transcription factor pathway and that KRAS-induced lung tumorigenesis is suppressed by expression of a degradation-resistant form of the IκBα inhibitor or by genetic deletion of IKKβ or the RELA/p65 subunit of NF-κB. Here, genetic and pharmacological approaches were utilized to inactivate IKK in human primary lung epithelial cells transformed by KRAS, as well as KRAS mutant lung cancer cell lines. Administration of the highly specific IKKβ inhibitor Compound A (CmpdA) led to NF-κB inhibition in different KRAS mutant lung cells and siRNA-mediated knockdown of IKKα or IKKβ reduced activity of the NF-κB canonical pathway. Next, we determined that both IKKα and IKKβ contribute to oncogenic properties of KRAS mutant lung cells, particularly when p53 activity is disrupted. Based on these results, CmpdA was tested for potential therapeutic intervention in the Kras-induced lung cancer mouse model (LSL-Kras (G12D)) combined with loss of p53 (LSL-Kras (G12D)/p53 (fl/fl)).
3.Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation.
Timm DE;Benveniste M;Weeks AM;Nisenbaum ES;Partin KM Mol Pharmacol. 2011 Aug;80(2):267-80. doi: 10.1124/mol.110.070243. Epub 2011 May 4.
At the dimer interface of the extracellular ligand-binding domain of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors a hydrophilic pocket is formed that is known to interact with two classes of positive allosteric modulators, represented by cyclothiazide and the ampakine 2H,3H,6aH-pyrrolidino(2,1-3',2')1,3-oxazino(6',5'-5,4)benzo(e)1,4-dioxan-10-one (CX614). Here, we present structural and functional data on two new positive allosteric modulators of AMPA receptors, phenyl-1,4-bis-alkylsulfonamide (CMPDA) and phenyl-1,4-bis-carboxythiophene (CMPDB). Crystallographic data show that these compounds bind within the modulator-binding pocket and that substituents of each compound overlap with distinct moieties of cyclothiazide and CX614. The goals of the present study were to determine 1) the degree of modulation by CMPDA and CMPDB of AMPA receptor deactivation and desensitization; 2) whether these compounds are splice isoform-selective; and 3) whether predictions of mechanism of action could be inferred by comparing molecular interactions between the ligand-binding domain and each compound with those of cyclothiazide and CX614. CMPDB was found to be more isoform-selective than would be predicted from initial binding assays.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related AMPAR Products

CAS 1467057-23-3 PF 06409577

PF 06409577
(CAS: 1467057-23-3)

PF 06409577 is a potent and selective allosteric activator of AMPK (EC50 values are 7 and >40000 nM for AMPKα1β1γ1 and AMPKα1β2γ1, respectively) for the potenti...

CAS 2259-96-3 Cyclothiazide

(CAS: 2259-96-3)

Cyclothiazide has been found to be a subunit-specific inhibitor of GABAC receptors and could be used as a diuretic agent as well as antihypertensive agent.

CAS 122306-11-0 Naspm

(CAS: 122306-11-0)

A poliamine amide as potent Spermidine uptake inhibitor.

CAS 173952-44-8 SYM 2206

SYM 2206
(CAS: 173952-44-8)

SYM 2206 is a potent and noncompetitive AMPA receptor antagonist (IC50 = 2.8 μM ) that exhibits anticonvulsant activity in vivo. SYM 2206 acts allosterically at...

CAS 1255517-78-2 ZK200775 hydrate

ZK200775 hydrate
(CAS: 1255517-78-2)

ZK200775 hydrate(Fanapanel; MPQX) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 &mu...

CAS 2036081-86-2 JNJ 55511118

JNJ 55511118
(CAS: 2036081-86-2)

JNJ 55511118 has been found to be an AMPA receptor modulator and could probably be used as an anticonvulsant.

CAS 72432-10-1 Aniracetam

(CAS: 72432-10-1)

Aniracetam is a nootropics and neuroprotective drug.

CAS 389888-02-2 (S)-CPW 399

(S)-CPW 399
(CAS: 389888-02-2)

(S)-CPW 399 has been found to be a subtype-selective weakly desensitising AMPA agonist.

Chemical Structure

CAS 380607-77-2 CMPDA

Quick Inquiry

Verification code

Featured Items